NervGen published expanded CONNECT SCI study data showing sustained, clinically meaningful improvements in function, independence, and quality of life for people with chronic spinal cord injury treated with NVG‑291. The company paired week‑16 outcomes with blinded exit interviews up to 364 days and reported biomarker changes linking reduced reticulospinal hyperactivity and increased corticospinal signaling. NervGen completed an FDA Type C meeting in September and said regulators confirmed multiple potential approval pathways for NVG‑291 as a first pharmacologic treatment for spinal cord injury. The dataset combines patient‑reported outcomes and electrophysiology measures to support both efficacy and a mechanistic basis for repair.